glp-1 drugs shortage FDA says of drug tirzepatide is over What Changed? The FDA's Clarification

Available data, primarily in individuals who received one dose of HEPLISAVB in the 28 days prior to or during pregnancy, do not suggest an increased risk of major birth defects and miscarriage

It protects hair follicles from oxidative stress and environmental damage

Certificates of analysis (COAs), batch information, and testing data are typically available for review, ensuring that researchers can verify each products specifications before incorporating it into their studies

The users who report the best before-and-after outcomes share several habits that amplify the peptide's fat-mobilizing effect

Parihar and Bhatt, 2023)